Abstract | BACKGROUND: AIM: METHODS: Rats were dosed (by mouth) for 7 days (b.d.) with either sulphasalazine (50 mg/kg), marimastat (40 mg/kg) or vehicle. TNBS- ethanol was administered rectally on the 4th day of dosing. On the last day of dosing, colons were removed and assessed for inflammation using myeloperoxidase activity, production of soluble TNFalpha (tumour necrosis factor alpha), clinical score and histological assessment. In addition, the bioavailability and effect of marimastat on a range of MMPs were assessed in-vitro. RESULTS: In this study we have confirmed that marimastat is a broad spectrum MMPI with a bioavailability of 5%. TNBS rats dosed with sulphasalazine had a significantly lower (P < 0.05) myeloperoxidase activity, TNFalpha production and a markedly lower clinical score. Similarly, rats dosed with marimastat had a significantly lower (P < 0.05) myeloperoxidase activity and clinical score, but the TNFalpha production was not significantly reduced. CONCLUSIONS:
|
Authors | A P Sykes, R Bhogal, C Brampton, C Chander, C Whelan, M E Parsons, J Bird |
Journal | Alimentary pharmacology & therapeutics
(Aliment Pharmacol Ther)
Vol. 13
Issue 11
Pg. 1535-42
(Nov 1999)
ISSN: 0269-2813 [Print] England |
PMID | 10571613
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Hydroxamic Acids
- Matrix Metalloproteinase Inhibitors
- Protease Inhibitors
- Tumor Necrosis Factor-alpha
- Trinitrobenzenesulfonic Acid
- marimastat
- Peroxidase
- Matrix Metalloproteinases
|
Topics |
- Animals
- Biological Availability
- Colitis
(chemically induced, drug therapy, pathology)
- Hydroxamic Acids
(pharmacokinetics, therapeutic use)
- Inflammatory Bowel Diseases
(chemically induced, drug therapy, pathology)
- Male
- Matrix Metalloproteinase Inhibitors
- Matrix Metalloproteinases
(metabolism)
- Peroxidase
(metabolism)
- Protease Inhibitors
(therapeutic use)
- Rats
- Rats, Wistar
- Trinitrobenzenesulfonic Acid
- Tumor Necrosis Factor-alpha
(metabolism)
|